MSB 1.49% $1.02 mesoblast limited

HF-MACE P3 [ PART 4 ], page-12

  1. 129 Posts.
    Oops, I need to correct my last mail (written too hastily - double negative)

    In response to hot tuna  commenting "I think it (the trial) already has failed" I meant to respond:

    " You are wrong in saying the trial has failed"

    And to remind all readers "The United States FDA has cleared the commencement of a 24-patient trial combining Mesoblast's proprietary allogeneic mesenchymal precursor cells (MPC's) with corrective heart surgery in children under the age of 5 with hypoplastic left heart syndrome (HLHS)" - April 3, 2017
    At the Boston Children's Hospital - ranked #1 in Pediatrics : Cardiology & Heart Surgery.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.